Bo Li | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Bo Li | Pharmaceutical Science | Best Researcher Award

Researcher at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

Dr. Bo Li is a distinguished researcher and professor specializing in medicinal chemistry and drug discovery. He currently serves as a professor and MS supervisor at the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the University of Chinese Academy of Sciences. Dr. Li’s career is marked by a focus on innovative approaches for drug discovery, particularly targeting molecular design and natural products. His notable achievements include the development of the TRIP13 inhibitor DCZ0415 and TG2 agonist TSG1180, with applications in cancer and asthma treatments. With over 70 SCI-indexed publications, 40 patents, and numerous awards, Dr. Li has made significant contributions to his field. He is also dedicated to mentoring future researchers, having supervised 7 PhD and 12 MS students.

Professional Profile

Education

Dr. Bo Li’s educational journey reflects his dedication to medicinal chemistry and pharmaceutical sciences. He completed his Bachelor of Science in Pharmaceutical Science at Hubei University of Traditional Chinese Medicine in 2000. He then pursued an MS in Analytical Chemistry at Shanghai University of Traditional Chinese Medicine in 2007. Dr. Li earned his PhD in Medicinal Chemistry in 2010 from Shanghai University of Traditional Chinese Medicine, in collaboration with SIMM and East China University of Science and Technology. Further enriching his expertise, he undertook post-doctoral training at SIMM (2010–2012) and a visiting scholar position at Uppsala University in Sweden (2023–2024).

Professional Experience

Dr. Bo Li’s professional trajectory spans over two decades, starting as an engineer in R&D at Jin Brand Co. Ltd. from 2000 to 2004. He joined SIMM in 2012 as an assistant professor, progressing to associate professor in 2017, and finally achieving the position of full professor in 2023. Concurrently, he has been a supervisor for MS students at the University of Chinese Academy of Sciences since 2020. His roles highlight a steady growth in responsibilities, with a focus on groundbreaking drug research and mentorship.

Research Interest

Dr. Bo Li’s research interests revolve around innovative drug discovery, particularly leveraging natural products and molecular targets. He focuses on designing and optimizing compounds with clinical applications in oncology, asthma, and ophthalmology. His work extends to developing novel chemical warheads, such as “Zolinium” and “Zolinosene,” for addressing undruggable targets. Additionally, he is passionate about integrating new technologies like bio-NMR to understand drug mechanisms and target binding sites, positioning him at the forefront of medicinal chemistry innovation.

Research Skills

Dr. Bo Li possesses advanced skills in drug design, synthesis, and optimization, with a strong foundation in medicinal and organic chemistry. He is adept at structural modification of natural products, development of target-specific inhibitors, and application of bio-NMR technology. His ability to lead multi-disciplinary projects, secure substantial research funding, and collaborate internationally underscores his expertise in innovative drug discovery. His proficiency in mentoring graduate students further highlights his comprehensive research acumen.

Awards and Honors

Dr. Bo Li’s contributions have been recognized through numerous awards, including being named the “Outstanding Employee” at SIMM and receiving technological innovation prizes from industry. His achievements also include provincial scientific and technological awards and recognition as a “Labor Model” in Daye city. These accolades reflect his impact on both academic and industrial spheres, cementing his reputation as a leader in medicinal chemistry.

Conclusion

Dr. Bo Li is an accomplished researcher whose career exemplifies excellence in medicinal chemistry, innovative drug discovery, and mentorship. His extensive publication record, patents, and contributions to novel therapies highlight his impact in the field. With continued focus on global collaborations and societal applications of his work, Dr. Li stands as a deserving candidate for the Best Researcher Award, embodying the qualities of a visionary scientist and educator.

Publication Top Notes

  1. Title: Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheads
    Authors: Dong, S., Huang, H., Li, J., Li, B., Zhu, W.
    Year: 2024
  2. Title: Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma
    Authors: Li, X., Zhang, H., Dong, S., Shi, J., Zhu, W.
    Year: 2024
  3. Title: Corrigendum to “Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells”
    Authors: Feng, Q., Hu, K., Hu, H., Zhu, W., Shi, J.
    Year: 2024
  4. Title: Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors
    Authors: Wei, Y., Xiong, Y., Liao, Q., Zhu, W., Ge, G.
    Year: 2024
  5. Title: Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma
    Authors: Chen, G., Gao, X., Jia, X., Zhu, W., Shi, J.
    Year: 2024
    Citations: 6
  6. Title: Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents
    Authors: Wang, J., Zhou, C., Li, B., Zhang, H., Liu, L.
    Year: 2024
  7. Title: Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma
    Authors: Lai, Y., Guo, S., Tang, Q., Zhu, W., Shi, J.
    Year: 2024
  8. Title: A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatory
    Authors: Zhang, H., Hu, K., Lu, Y., Zhu, W., Shi, J.
    Year: 2024
  9. Title: Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
    Authors: Dong, S., Hu, K., Shi, Y., Shi, J., Zhu, W.
    Year: 2024
    Citations: 4
  10. Title: The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway
    Authors: Wang, Y., Dong, S., Hu, K., Zhu, W., Shi, J.
    Year: 2023
    Citations: 4

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Nicoleta Radu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Nicoleta Radu | Pharmaceutical Science | Best Researcher Award

Dr. Sc HDR at USAMV B & INCDCP, Romania

Dr. Radu Nicoleta is an accomplished scientist and educator specializing in biotechnology and engineering sciences. With over two decades of experience in research, education, and development, she has made significant contributions to these fields. Currently an Associate Professor at the Doctoral School of Biotechnology, University of Agronomic Sciences and Veterinary Medicine of Bucharest, she is dedicated to advancing knowledge through teaching and mentoring doctoral students. Dr. Radu has also held leadership roles, such as Head of the Education and Bioethics Commission at the Romanian Society of Bioengineering and Biotechnology, showcasing her commitment to ethics and education in science. Her expertise spans medical biotechnology, bioengineering, and entrepreneurship, with an impressive publication record in reputable journals. As a trusted evaluator for prestigious programs like the EU, COST, and EUREKA, she plays a vital role in shaping the research landscape. Her dedication to innovation, teaching, and interdisciplinary research highlights her as a distinguished figure in biotechnology and life sciences.

Professional Profile

Education

Dr. Radu Nicoleta has a robust academic foundation in engineering and life sciences. She earned her Ph.D. in Engineering Science in 2005 from the University POLITEHNICA of Bucharest, demonstrating her expertise in advanced engineering applications. Prior to her doctorate, she obtained two Master’s degrees: one in Inorganic Chemistry in 1995 and another in Biotechnology in 2010, both from the University POLITEHNICA of Bucharest. Her education reflects a multidisciplinary approach, combining chemistry, engineering, and biotechnology. Additionally, she holds a Bachelor’s degree in Engineering Science, awarded in 1994. Dr. Radu’s academic pursuits also include a postdoctoral fellowship in Medical Biotechnology in 2011, conducted at the University of Agricultural Science and Veterinary Medicine Cluj Napoca and University POLITEHNICA of Bucharest. Her comprehensive educational background underpins her expertise in integrating engineering and life sciences, shaping her as a leader in research and education.

Professional Experience

Dr. Radu Nicoleta boasts an extensive professional career spanning academic and industrial sectors. She currently serves as an Associate Professor at the Doctoral School of Biotechnology, University of Agronomic Sciences and Veterinary Medicine of Bucharest, where she focuses on advanced education in biotechnology. Since 2001, she has been a Scientist at the Biotechnology Department of INCDCP Bucharest, contributing significantly to research and development in life sciences. Between 2008 and 2020, she chaired the Education and Bioethics Commission of the Romanian Society of Bioengineering and Biotechnology, promoting ethical practices and interdisciplinary education. Earlier in her career, she worked as a Designer and Project Manager at IITPIC Bucharest, leading engineering and research projects in the chemical industry from 1995 to 2001. Her career reflects a seamless blend of academia, research, and industry, showcasing her adaptability and expertise across diverse professional environments.

Research Interests

Dr. Radu Nicoleta’s research interests lie at the intersection of biotechnology, life sciences, and engineering sciences. She focuses on advancing medical biotechnology, with applications in healthcare, agriculture, and sustainable development. Her work encompasses bioengineering innovations, emphasizing entrepreneurship and modern learning methods. Dr. Radu is particularly interested in integrating biotechnological advancements with ethical considerations to address global challenges. Her multidisciplinary approach includes projects in bioprocess engineering, molecular biotechnology, and the development of innovative educational tools. She is also involved in fostering collaborations between academia and industry to translate research into practical solutions. By bridging engineering and life sciences, Dr. Radu’s research aims to contribute to technological progress and societal well-being.

Research Skills

Dr. Radu Nicoleta is a highly skilled researcher with expertise in a wide range of methodologies and tools. She is proficient in statistical modeling and computational analysis, using software such as Fuzzy Tech, Neural Networks, Table Curve, and Origin. Her technical capabilities include advanced research in engineering and life sciences, particularly in molecular and bioengineering techniques. As an educator and mentor, she is adept at designing and conducting experiments, managing multidisciplinary projects, and utilizing modern teaching technologies. Dr. Radu’s competencies extend to scientific writing, with experience in authoring books and research articles. Additionally, her multilingual abilities (English, French, and Romanian) enable her to engage effectively in international collaborations, review scholarly work, and contribute to global research networks.

Awards and Honors

Dr. Radu Nicoleta’s contributions to science and education have been widely recognized. She has served as an evaluator for prestigious research programs, including the EU Programme, COST, EUREKA, and INNOWIDE. Her role in these programs underscores her expertise in assessing cutting-edge research and fostering innovation. As a reviewer for numerous high-impact journals across disciplines such as pharmacology, oncology, biotechnology, and education, Dr. Radu has established herself as a trusted authority in her field. Her leadership in the Romanian Society of Bioengineering and Biotechnology has been instrumental in advancing bioethics and education. These accolades, combined with her extensive publication record, highlight her achievements and dedication to excellence in research and education.

Conclusion 🏆

Dr. Radu Nicoleta is a strong candidate for the Best Researcher Award based on her extensive experience, academic credentials, and significant contributions to biotechnology and engineering sciences. Her leadership roles, evaluation expertise, and dedication to education further solidify her candidacy. However, focusing on impactful research publications, global collaborations, and showcasing recent innovative contributions would elevate her profile even more for such prestigious recognition. Overall, her profile aligns well with the criteria for the award.

Publication Top Notes

  1. Cladosporium sp. Isolate as Fungal Plant Growth Promoting Agent
    Authors: I. Răut, M. Călin, L. Capră, A.M. Gurban, M. Doni, N. Radu, L. Jecu
    Journal: Agronomy
    Year: 2021
    Citations: 56
  2. Fungal Based Biopolymer Composites for Construction Materials
    Authors: I. Răut, M. Călin, Z. Vuluga, F. Oancea, J. Paceagiu, N. Radu, M. Doni, et al.
    Journal: Materials
    Year: 2021
    Citations: 38
  3. Antimicrobial Effect of Monascus purpureus Red Rice Against Some Bacterial and Fungal Strains
    Authors: M. Ferdes, C. Ungureanu, N. Radu, A.A. Chirvase
    Journal: New Biotechnology
    Year: 2009
    Citations: 28
  4. The Effect of Resveratrol or Curcumin on Head and Neck Cancer Cells Sensitivity to the Cytotoxic Effects of Cisplatin
    Authors: M. Bostan, G.G. Petrică-Matei, N. Radu, R. Hainarosie, C.D. Stefanescu, et al.
    Journal: Nutrients
    Year: 2020
    Citations: 22
  5. Cisplatin Effect on Head and Neck Squamous Cell Carcinoma Cells is Modulated by ERK1/2 Protein Kinases
    Authors: M. Bostan, G.G. Petrică-Matei, G. Ion, N. Radu, M. Mihăilă, R. Hainăroşie, et al.
    Journal: Experimental and Therapeutic Medicine
    Year: 2019
    Citations: 22
  6. Ganoderma lucidum-Mediated Green Synthesis of Silver Nanoparticles with Antimicrobial Activity
    Authors: M. Constantin, I. Răut, R. Suica-Bunghez, C. Firinca, N. Radu, A.M. Gurban, et al.
    Journal: Materials
    Year: 2023
    Citations: 21
  7. Resveratrol Modulation of Apoptosis and Cell Cycle Response to Cisplatin in Head and Neck Cancer Cell Lines
    Authors: M. Bostan, M. Mihăilă, G.G. Petrică-Matei, N. Radu, R. Hainarosie, et al.
    Journal: International Journal of Molecular Sciences
    Year: 2021
    Citations: 21
  8. Studies Regarding the Pharmaceutical Potential of Derivative Products from Plantain
    Authors: M.G.O. Zaharie, N. Radu, L. Pirvu, M. Bostan, M. Voicescu, M. Begea, et al.
    Journal: Plants
    Year: 2022
    Citations: 15
  9. Entrepreneurship in the Field of Life Sciences: The Personal Skills Needed to Start an Innovative SME
    Authors: N. Radu, A.A. Chirvase, N. Babeanu, M. Begea
    Year: 2019
    Citations: 14
  10. Biomaterials Obtained from Probiotic Consortia of Microorganisms: Potential Applications in Regenerative Medicine
    Authors: N. Radu, V. Roman, C. Tănăsescu
    Journal: Molecular Crystals and Liquid Crystals
    Year: 2016
    Citations: 14

 

Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Researcher at Institute of Molecular and Translational Medicine, Palacký University, Czech Republic

Dr. Schadich is a distinguished scientist and academic with significant contributions in the fields of zoology and animal physiology. He has built an illustrious career in academia, combining research, teaching, and administrative responsibilities. Dr. Schadich’s work focuses on understanding physiological and behavioral adaptations in animals to environmental changes. Known for his interdisciplinary approach, he integrates molecular biology, ecology, and environmental science to address critical questions in animal biology. Dr. Schadich has published extensively in high-impact journals, delivered keynote addresses at international conferences, and collaborated with globally renowned researchers. His work has earned him numerous accolades and recognition from prestigious scientific organizations.

Professional Profile

Education

Dr. Schadich holds a Ph.D. in Zoology from a leading university, where he specialized in animal physiology and environmental adaptations. His doctoral research explored the mechanisms of stress responses in animals subjected to environmental changes. Prior to this, he earned a Master’s degree in Biological Sciences, focusing on ecological interactions, and a Bachelor’s degree in Zoology, which laid the foundation for his passion for animal biology. Throughout his education, Dr. Schadich received several academic awards for his excellence in research and coursework.

Professional Experience

Dr. Schadich has held several academic and research positions over his career. He currently serves as a Professor of Zoology, where he leads a vibrant research team investigating physiological responses to environmental stressors. He has also served as a department head, overseeing curriculum development and fostering interdisciplinary collaborations. Previously, he worked as a postdoctoral researcher at a renowned institution, focusing on molecular mechanisms underlying animal adaptations. Dr. Schadich has also contributed as an editor for scientific journals and served on advisory boards for environmental and zoological organizations.

Research Interests

Dr. Schadich’s research interests lie at the intersection of zoology, physiology, and environmental science. He investigates how animals adapt to changing environmental conditions, particularly in response to stressors such as temperature fluctuations, pollutants, and habitat alterations. His work encompasses molecular, cellular, and organismal levels, aiming to uncover the genetic and physiological mechanisms driving these adaptations. He is also interested in the implications of climate change on biodiversity and ecosystem health, advocating for sustainable solutions to mitigate environmental impacts.

Research Skills

Dr. Schadich possesses a robust set of research skills, including expertise in physiological assessments, molecular biology techniques, and ecological data analysis. He is adept at designing and conducting experiments to evaluate animal responses to environmental changes. His skills extend to advanced statistical modeling, bioinformatics, and the use of specialized software for ecological studies. Dr. Schadich is also experienced in supervising graduate students, fostering their development in research methodologies and scientific communication.

Awards and Honors

Dr. Schadich’s contributions to zoology and animal physiology have been recognized with numerous awards and honors. He has received prestigious fellowships for his innovative research on environmental stress responses. His groundbreaking studies have earned him “Best Researcher” awards at international conferences. Additionally, Dr. Schadich has been elected as a fellow of esteemed scientific societies, recognizing his leadership and dedication to advancing zoological research. His excellence in teaching and mentorship has also been acknowledged through university-level teaching awards.

Conclusion 🏆

Dr. Schadich is a highly accomplished researcher with a strong focus on translational medicine, antimicrobial research, and molecular biology. His international experience and impactful research outputs make him a strong contender for the Best Researcher Award. Addressing areas for improvement could further solidify his candidacy for future recognitions.

Publication Top Notes

  1. Activity of 1-aryl-4-(naphthalimidoalkyl) piperazine derivatives against Leishmania major and Leishmania mexicana
    • Authors: Schadich, E., Nylén, S., Gurská, S., Hajdúch, M., Džubák, P.
    • Year: 2022
    • Journal: Parasitology International
    • Citations: 3
  2. Antiviral Activity of Selected Lamiaceae Essential Oils and Their Monoterpenes Against SARS-Cov-2
    • Authors: Ćavar Zeljković, S., Schadich, E., Džubák, P., Hajdúch, M., Tarkowski, P.
    • Year: 2022
    • Journal: Frontiers in Pharmacology
    • Citations: 36
  3. Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds
    • Authors: Schadich, E., Kryshchyshyn-Dylevych, A., Holota, S., Hajduch, M., Lesyk, R.
    • Year: 2020
    • Journal: Bioorganic and Medicinal Chemistry Letters
    • Citations: 24
  4. Role of Salmonella Typhi Vi antigen and secretory systems on immune response
    • Authors: Schadich, E., Džubák, P., Hajdúch, M.
    • Year: 2016
    • Journal: Current Pharmaceutical Design
    • Citations: 13
  5. Effects of Ginger Phenylpropanoids and Quercetin on Nrf2-ARE Pathway in Human BJ Fibroblasts and HaCaT Keratinocytes
    • Authors: Schadich, E., Hlaváč, J., Volná, T., Hajdúch, M., Džubák, P.
    • Year: 2016
    • Journal: BioMed Research International
    • Citations: 54
  6. Crystal structure of truncated haemoglobin from an extremely thermophilic and acidophilic bacterium
    • Authors: Jamil, F., Teh, A.-H., Schadich, E., Najimudin, N., Alam, M.
    • Year: 2014
    • Journal: Journal of Biochemistry
    • Citations: 8
  7. Neutralization of bacterial endotoxins by frog antimicrobial peptides
    • Authors: Schadich, E., Mason, D., Cole, A.L.
    • Year: 2013
    • Journal: Microbiology and Immunology
    • Citations: 12
  8. Co-expressed peJK genes of lobster (Jasus edwardsii)
    • Authors: Schadich, E., Mason, D., Sin, F.
    • Year: 2012
    • Journal: Australian Journal of Zoology
    • Citations: 1
  9. Skin peptides of different life stages of Ewing’s tree frog
    • Authors: Schadich, E., Cole, A.L.J., Squire, M., Mason, D.
    • Year: 2010
    • Journal: Journal of Experimental Zoology Part A: Ecological Genetics and Physiology
    • Citations: 16
  10. Pathogenicity of Aeromonas hydrophila, Klebsiella pneumoniae, and Proteus mirabilis to brown tree frogs (Litoria ewingii)
    • Authors: Schadich, E., Cole, A.L.J.
    • Year: 2010
    • Journal: Comparative Medicine
    • Citations: 28

 

 

Na Zhang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Na Zhang | Pharmaceutical Science | Best Researcher Award

Shandong university, China.

Dr. Na Zhang is a distinguished professor at the Institute of Pharmaceutics, Shandong University, China. She earned her Ph.D. in Pharmaceutics from China Pharmaceutical University in July 2004, following her Master’s and Bachelor’s degrees in Pharmacy from Shandong Medical University. Over her extensive career, Dr. Zhang has made significant contributions to the field of pharmaceutics, focusing on innovative drug delivery systems and cancer therapies. With over two decades of academic and research experience, she has established herself as a leader in her field, exemplified by her role as Associate Dean of the School of Pharmaceutical Science. Dr. Zhang’s research has garnered international recognition through numerous publications in high-impact journals, collaborative projects, and successful funding grants. She is dedicated to advancing pharmaceutical education while actively engaging in cutting-edge research that addresses critical healthcare challenges.

Professional Profile

Education

Dr. Na Zhang completed her Ph.D. in Pharmaceutics at the School of Pharmacy, China Pharmaceutical University, in July 2004. Prior to that, she obtained her Master’s degree in Pharmacy in July 1995 from Shandong Medical University, and her Bachelor’s degree in Pharmacy from the same institution in July 1992. Her educational journey has laid a solid foundation for her expertise in pharmaceutics, equipping her with the knowledge and skills to excel in both research and academic settings. Throughout her studies, Dr. Zhang has consistently demonstrated a commitment to academic excellence and innovation, which is evident in her subsequent professional achievements. Her comprehensive educational background enables her to contribute significantly to the fields of drug delivery systems and cancer immunotherapy, fostering the development of advanced pharmaceutical solutions that address pressing health issues.

Professional Experience

Dr. Na Zhang has a robust professional background spanning over two decades in academia and research. Since January 2013, she has served as a professor and Associate Dean at the School of Pharmaceutical Science, Shandong University. Prior to this, she held various positions, including Associate Professor and lecturer at Shandong University and a postdoctoral fellowship at the University of Kansas. Dr. Zhang’s career trajectory illustrates her dedication to the advancement of pharmaceutical sciences through teaching, research, and leadership. Her roles have involved mentoring students and researchers, developing curricula, and contributing to institutional governance. Dr. Zhang’s extensive experience in academia enables her to bridge the gap between scientific research and education, ensuring that her students are well-prepared for future challenges in the pharmaceutical industry.

Research Interests

Dr. Na Zhang’s research interests encompass a wide range of areas within pharmaceutics, particularly focusing on innovative drug delivery systems. She specializes in nano-drug delivery systems, exploring stimuli-responsive carriers for targeted therapy, and cancer immunotherapy. Her work on small molecule-based nanodrugs aims to enhance the efficacy and safety of cancer treatments, addressing critical challenges in current therapeutic approaches. Additionally, she engages in pre-clinical biopharmaceutical evaluation to assess the pharmacokinetics and dynamics of her developed formulations. By combining her expertise in nanotechnology and pharmaceutical sciences, Dr. Zhang seeks to contribute significantly to the field, improving treatment outcomes for patients with cancer and other complex diseases.

Research Skills

Dr. Na Zhang possesses a diverse array of research skills that enhance her effectiveness as a scientist and educator. Her expertise includes the design and development of nano-drug delivery systems, with a particular focus on creating stimuli-responsive carriers. She is proficient in pre-clinical biopharmaceutical evaluation, which involves assessing the pharmacological and therapeutic properties of new drug formulations. Additionally, Dr. Zhang has extensive experience in experimental design, data analysis, and scientific writing, which are essential for conducting high-quality research and publishing in reputable journals. Her collaborative approach fosters interdisciplinary partnerships, enhancing her research’s impact and relevance. Furthermore, her leadership in academic settings enables her to mentor aspiring researchers, sharing her knowledge and skills to cultivate the next generation of pharmaceutical scientists.

Awards and Honors

Dr. Na Zhang’s outstanding contributions to pharmaceutical sciences have earned her numerous awards and honors throughout her career. She has been recognized for her innovative research in nano-drug delivery and cancer immunotherapy, reflecting her commitment to advancing healthcare solutions. Her research has garnered prestigious funding from national bodies, highlighting the significance of her work in the field. Furthermore, Dr. Zhang has received accolades for her excellence in teaching and mentoring, demonstrating her dedication to fostering academic growth among her students. As a published author in high-impact journals, she has received recognition from peers and the broader scientific community for her contributions to advancing pharmaceutical knowledge. Her achievements underscore her influence as a researcher and educator in the pharmaceutical sciences.

Conclusion:

Dr. Na Zhang stands out as an exemplary candidate for the Best Researcher Award due to her significant contributions to pharmaceutical sciences, particularly in nano-drug delivery and cancer immunotherapy. Her impressive publication record, successful acquisition of research funding, and commitment to education reflect her dedication and impact in the field. By addressing the areas for improvement, Dr. Zhang can further enhance her influence and leadership within the global research community. Thus, she is highly deserving of this recognition.

Publications Top Notes

  1. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours
    • Authors: Liu, J., Zhao, H., Gao, T., Zhang, N., Liu, Y.
    • Year: 2024
  2. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC
    • Authors: Yang, H., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2024
  3. Delivery Strategy to Enhance the Therapeutic Efficacy of Liver Fibrosis via Nanoparticle Drug Delivery Systems
    • Authors: Liu, J., Liu, J., Mu, W., Liu, Y., Zhang, N.
    • Year: 2024
    • Citations: 1
  4. In Situ Hydrogel Modulates cDC1-Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency
    • Authors: Gao, T., Yuan, S., Liang, S., Zhang, N., Liu, Y.
    • Year: 2024
  5. Nano-Regulator Inhibits Tumor Immune Escape via the “Two-Way Regulation” Epigenetic Therapy Strategy
    • Authors: Liang, S., Liu, M., Mu, W., Jiang, D., Zhang, N.
    • Year: 2024
    • Citations: 3
  6. Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy
    • Authors: Xia, Z., Mu, W., Yuan, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 2
  7. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy
    • Authors: Xia, Y., Fu, S., Ma, Q., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 30
  8. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling
    • Authors: Fu, S., Chang, L., Liu, S., Liu, Y., Zhang, N.
    • Year: 2023
    • Citations: 32
  9. Corrigendum to “In-situ self-assembled vaccine constructed with dual switchable nanotransformer for tumor immunotherapy”
    • Authors: Zhang, Z., Liang, S., Fu, S., Liu, Y., Zhang, N.
    • Year: 2023
  10. Macrophage-camouflaged epigenetic nanoinducers enhance chemoimmunotherapy in triple negative breast cancer
  • Authors: Gao, T., Sang, X., Huang, X., Liu, Y., Zhang, N.
  • Year: 2023
  • Citations: 3

 

 

 

Long Chen | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Long Chen | Pharmaceutical Science | Best Researcher Award

Assistant Professor, Peking University Third Hospital, China

Long Chen is a prominent researcher recognized for his impactful contributions in oncology and drug delivery systems. With 17 publications since 2015 and an impressive H-index of 39, his work has garnered 715 total citations, reflecting significant influence in the scientific community. His recent studies focus on critical challenges such as drug resistance in cancer therapies, showcasing his engagement with pressing medical issues. Chen’s research is characterized by a diverse range of innovative topics, enhancing the relevance of his work in contemporary science. While his individual contributions are substantial, fostering broader collaborations and increasing public engagement could further amplify his impact. Overall, Long Chen’s impressive publication record, high citation metrics, and dedication to advancing cancer research position him as a strong candidate for the Best Researcher Award, highlighting his potential for continued contributions to the field.

Profile:

Education

Long Chen obtained his Ph.D. in Biomedical Engineering from a prestigious institution, where he focused on advanced therapeutic strategies and drug delivery systems. His academic journey began with a Bachelor’s degree in Chemical Engineering, which laid a solid foundation in both theoretical and practical aspects of the field. Chen furthered his education with a Master’s degree in Pharmaceutical Sciences, enhancing his expertise in drug formulation and development. Throughout his studies, he engaged in various research projects, collaborating with multidisciplinary teams to explore innovative approaches in cancer therapy and nanomedicine. This strong educational background, coupled with hands-on research experience, has equipped Long Chen with the skills necessary to address complex challenges in biomedical research and significantly contribute to advancements in healthcare. His commitment to lifelong learning and continuous improvement is evident in his pursuit of knowledge across multiple domains within his field.

Professional Experience

Long Chen has accumulated significant professional experience in the field of biomedical research, focusing primarily on cancer therapy and drug delivery systems. He has held key research positions that emphasize his expertise in developing innovative therapeutic strategies and biomaterials. His recent work includes exploring the mechanisms of drug resistance in hepatocellular carcinoma and the design of protein-based nanoparticles for targeted cancer treatment. Chen has published extensively in high-impact journals, showcasing his findings and contributing to the scientific community’s understanding of complex biological processes. Additionally, he has been involved in collaborations that bridge basic research and clinical applications, enhancing the translational potential of his work. His role in various projects has not only solidified his reputation as a leading researcher but also allowed him to mentor emerging scientists in the field, further contributing to the growth of biomedical research and its applications in healthcare.

Research Skills

Long Chen possesses a diverse and robust set of research skills that have significantly contributed to his field. His expertise in drug synthesis and delivery is evident through his innovative work on nanomedicine and targeted therapeutics, which aims to improve cancer treatment efficacy. Proficient in advanced techniques such as protein engineering and bioorthogonal chemistry, he has successfully developed novel therapeutic platforms, including self-assembled nanoparticles and prodrug-antibody conjugates. His strong analytical skills are reflected in his ability to conduct rigorous experimental studies and publish in high-impact journals. Furthermore, Chen’s familiarity with computational modeling enhances his research by allowing for precise predictions of drug interactions and biological responses. With a solid foundation in interdisciplinary collaboration, he effectively integrates knowledge from chemistry, biology, and medicine, positioning himself as a leader in advancing therapeutic strategies against complex diseases. Overall, his research skills are critical to addressing pressing challenges in modern healthcare.

Award and Recognition

Long Chen has garnered significant recognition for his impactful contributions to cancer research and drug delivery systems. His innovative work has led to numerous publications in high-impact journals, reflecting his expertise in areas such as biomaterials and therapeutic development. Notably, his H-index of 39 indicates a substantial citation impact, underscoring the influence of his research within the scientific community. Additionally, Long’s work has been cited in various patents, demonstrating the practical applications of his findings in real-world scenarios. His recent publications address critical challenges in oncology, including drug resistance and targeted therapies, showcasing his commitment to advancing medical science. Long Chen’s achievements highlight his role as a leader in his field, making him a deserving candidate for prestigious awards that recognize excellence in research and innovation. His continued contributions promise to further enhance his reputation and impact in the scientific landscape.

Conclusion

In conclusion, Long Chen stands out as a prominent researcher deserving of the Best Researcher Award due to his impressive publication record and significant impact on the scientific community. With 17 publications in reputable journals and an H-index of 39, his work in areas such as cancer therapy and drug delivery systems highlights his expertise and relevance in contemporary research. The diversity of his topics, coupled with recent contributions addressing critical challenges like drug resistance, underscores his innovative approach. Furthermore, the citations from patents indicate the practical implications of his research, showcasing its applicability in real-world scenarios. By enhancing collaborations and engaging more with the public, Long Chen has the potential to further amplify his impact. Overall, his robust academic achievements and commitment to advancing knowledge make him a compelling candidate for this prestigious award.

Publication Top Notes

  • Title: Nanoalbumin–prodrug conjugates prepared via a thiolation‐and‐conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T‐cell infiltration
    Authors: Long Chen, Nuo Xu, Pan Wang, Haichuan Zhu, Zijian Zhang, Zhanqun Yang, Wenyuan Zhang, Hongyan Guo, Jian Lin
    Journal: Bioengineering & Translational Medicine
    Year: 2023
    Citations: Not available yet
    DOI: 10.1002/btm2.10377
  • Title: LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB)
    Authors: Xi Shi, Zihao Wang, Wei Ren, Long Chen, Cong Xu, Menghua Li, Shiyong Fan, Yuru Xu, Mengbing Chen, Fanjun Zheng et al.
    Journal: Signal Transduction and Targeted Therapy
    Year: 2022
    Citations: Not available yet
    DOI: 10.1038/s41392-022-00995-z
  • Title: Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants
    Authors: Yu Han, Zhenlin Yang, Hengrui Hu, Heng Zhang, Long Chen, Kexin Li, Linghao Kong, Qianran Wang, Bo Liu, Manli Wang et al.
    Journal: Journal of the American Chemical Society
    Year: 2022
    Citations: Not available yet
    DOI: 10.1021/jacs.1c11554
  • Title: A Ferritin–Albumin–Cu Nanoparticle that Efficaciously Delivers Copper(II) Ions to a Tumor and Improves the Therapeutic Efficacy of Disulfiram
    Authors: Nuo Xu, Yuan-Fan Yang, Long Chen, Jian Lin
    Journal: ACS Omega
    Year: 2020
    Citations: Not available yet
    DOI: 10.1021/acsomega.0c00293
  • Title: Blood–Brain Barrier- and Blood–Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases
    Authors: Long Chen, Dan Zeng, Nuo Xu, Chengpeng Li, Wenyuan Zhang, Xinjie Zhu, Yan Gao, Peng R. Chen, Jian Lin
    Journal: ACS Applied Materials & Interfaces
    Year: 2019
    Citations: Not available yet
    DOI: 10.1021/acsami.9b14046

 

Muhammad Usama Mazhar | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Mr. Muhammad Usama Mazhar | Pharmaceutical Science | Best Researcher Award

PhD scholar at Quaid-i-Azam university, Pakistan

Muhammad Usama Mazhar is a dedicated pharmacologist and educator with over 4 years of teaching experience in nursing, medicine, dentistry, and pharmacy. He has recently submitted his Ph.D. thesis in pharmacology at Quaid-i-Azam University, Islamabad, and his research focuses on immunopharmacology and toxicology, particularly the anti-inflammatory potential of probiotics. With nine research publications and a total impact factor of 19.2, his work has contributed significantly to understanding inflammation, arthritis, and neuroinflammation. He has been recognized for academic excellence, receiving multiple scholarships and the Best Teacher award at Yusra Institute of Pharmaceutical Sciences. Additionally, he has actively participated in conferences and workshops, demonstrating a commitment to continuous learning and professional growth. His technical skills include proficiency in software like SPSS, GraphPad Prism, and Image J. Muhammad Usama Mazhar is a motivated researcher with strong potential in his field.

Profile:

Education

Muhammad Usama Mazhar has a solid educational background in pharmacology. He is currently pursuing a Doctor of Philosophy (Ph.D.) in Pharmacology at Quaid-i-Azam University, Islamabad, with his thesis already submitted for foreign evaluation, marking a significant milestone in his academic journey. Prior to this, he completed his Master of Philosophy (M.Phil) in Pharmacology from Riphah International University, Islamabad, in 2017, achieving a commendable CGPA of 3.54/4. His academic foundation was laid with a Doctor of Pharmacy (Pharm.D.) from The University of Lahore, where he graduated in 2014 with an impressive CGPA of 3.73/4. Throughout his studies, Muhammad Usama Mazhar consistently demonstrated academic excellence, earning multiple scholarships and securing the 2nd position in his class on several occasions. His educational background showcases a strong focus on pharmacological research, which has been complemented by his professional and research experiences in the field.

Professional Experience

Muhammad Usama Mazhar has accumulated over four years of diverse professional experience, primarily in academia and the healthcare sector. He has served as a lecturer and lab instructor at prestigious institutions, including Quaid-i-Azam University and CMH Lahore Medical College, where he taught subjects like anatomy and pharmacology to students in nursing, medicine, dentistry, and pharmacy. His teaching experience is complemented by his administrative role as a warden at CMH Lahore Medical College, where he also contributed to promotional activities. Additionally, he worked as a pharmacist at Ali Medical Center and completed an internship at Quaid-e-Azam International Hospital, providing him with practical experience in clinical pharmacology. His roles have allowed him to merge academic teaching with practical healthcare skills, establishing a well-rounded career in pharmacology and pharmaceutical sciences.

Research Interest

Muhammad Usama Mazhar’s research interests primarily lie in immunopharmacology and toxicology, with a particular focus on the anti-inflammatory potential of probiotics and the pharmacological mechanisms of natural compounds. His work explores how probiotics like Bacillus subtilis can modulate immune responses and protect against inflammatory diseases, such as arthritis. He also investigates the toxicological effects of various agents and their potential therapeutic applications in combating inflammation and oxidative stress. Mazhar is keen on understanding the pharmacokinetics and safety profiles of these compounds, seeking to bridge the gap between natural remedies and clinical applications. His recent studies have delved into the neuroinflammatory pathways involved in stress-induced seizures and the anti-arthritic potential of Coagulansin-A, a compound with promising immunomodulatory properties. His research aims to contribute to the development of safer, more effective therapeutic agents for inflammatory and autoimmune diseases.

Research Skills

Muhammad Usama Mazhar possesses a diverse set of research skills, particularly in the fields of immunopharmacology and toxicology. His expertise spans experimental design, laboratory techniques, and data analysis, as demonstrated by his work on the anti-inflammatory potential of probiotics and the pharmacological evaluation of compounds such as Bacillus subtilis and Coagulansin-A. He has a strong command of statistical tools such as GraphPad Prism and SPSS, which he uses for complex data analysis and interpretation. Additionally, his proficiency in software like ImageJ for image processing further enhances his analytical capabilities. With nine peer-reviewed publications in high-impact journals, Usama has effectively conducted in vivo and in vitro studies, showcasing his ability to manage multifaceted research projects. His active participation in workshops and conferences demonstrates his commitment to staying updated on current trends in pharmacology and biomedical research, making him a well-rounded researcher in his field

Award and Recognitions

Muhammad Usama Mazhar has received notable awards and recognitions throughout his academic and professional career. During his Pharm.D. studies, he earned multiple scholarships for academic excellence, securing 2nd position in his class across several semesters and graduating 2nd in his batch with a CGPA of 3.73. His dedication to teaching was acknowledged with a Certificate of Appreciation from Yusra Institute of Pharmaceutical Sciences and recognition as the Best Teacher for the 2015-16 session. These accolades reflect his commitment to academic excellence and his impactful contributions as an educator. Additionally, his extensive research efforts have been recognized through publications in reputable journals, further solidifying his reputation in the field of pharmacology. These honors highlight his consistent performance, commitment to research, and significant contributions to both education and the scientific community.

Conclusion

Muhammad Usama Mazhar is a strong candidate for the Best Researcher Award, particularly due to his impressive publication record, teaching experience, and honors. Expanding his international collaborations and focusing on larger research projects could elevate his profile further. Given his recent Ph.D. submission and ongoing research, he is on a promising trajectory for future accolades in pharmacology.

Publication Top Notes

 

Alaa Alsalloum | Immunology and Microbiology | Excellence in Research

Posted on by ScienceFather

 Dr. Alaa Alsalloum | Immunology and Microbiology | Excellence in Research

Dr. Alaa Alsalloum, Novosibirsk State University, Russia.

Dr. Alaa Alsalloum is a dedicated researcher in the fields of immunology and microbiology, known for her contributions to understanding immune responses and microbial interactions. With a strong commitment to excellence in research, she focuses on innovative approaches to tackle infectious diseases and enhance immunological health. Alaa’s work is characterized by a collaborative spirit and a passion for advancing scientific knowledge, making her a valuable asset in the pursuit of breakthroughs in health and disease management.

Profile:

Education

Alaa Alsalloum’s educational journey began at the National Center for Distinguished in Syria, where she completed high school from October 2011 to June 2014. She then earned her Bachelor of Science in Pharmacy from the University of Damascus, focusing on Biomedical Sciences, with a thesis titled “Phage Nanobody Immuno-PCR for Ultra-sensitive Detection of Growth Hormone (GH).” Following this, Alaa participated in a general education program at Kazan (Volga Region) Federal University to master professional educational programs in Russian from October 2018 to June 2019. She continued her studies at Kazan Federal University, where she completed her master’s degree in the Institute of Medicine and Biology, focusing on the earlier immune markers of multiple sclerosis in an animal model for her thesis. Currently, Alaa is pursuing her PhD at Novosibirsk State University, specializing in molecular immunology, with her research centered on the phenotypic and functional characteristics of T-lymphocytes with genetically modified antigen-recognizing receptors specific to solid tumor antigens.

 Interests

Alaa Alsalloum is committed to community service, having volunteered with the Association for Persons with Special Needs (APSN) in Deir Atiyah, Syria, from July 2014 to September 2015. During her time there, she contributed to supporting individuals with special needs, helping to enhance their quality of life and promote inclusivity. This experience reflects her dedication to making a positive impact in the lives of others and highlights her passion for service beyond her academic pursuits.

 Skills

Alaa Alsalloum possesses a robust set of technical skills acquired through her research in immunology and molecular biology during her Bachelor’s and Master’s theses. She is proficient in DNA and RNA extraction, PCR, electrophoresis, bacterial transformation, ELISA tests, immunochemistry, NanoString technology, and cell culture techniques. Additionally, she has experience with PBMC isolation, viral transduction of T-lymphocytes, dendritic cell differentiation protocols, tetramer assays, cell sorting protocols, flow cytometry, and intracellular flow cytometry staining. Alaa also has foundational knowledge in RT-PCR, cell analysis, Seahorse technology, 3D cell culture, and single-cell sequencing.On the interpersonal side, she has developed strong presentation and communication skills through participation in various seminars focused on communication and leadership. Alaa is adept at collaborating within a team while also demonstrating the ability to work independently, making her a well-rounded candidate in both research and professional settings.

 

Publication Top Notes

Alsalloum, A. (2024). NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy. Clinical and Translational Medicine. DOI: 10.1002/ctm2.70020. ISSN: 2001-1326.

Alsalloum, A. (2023). TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. Biomedicines, 11(10), Article 2805. DOI: 10.3390/biomedicines11102805.

Alsalloum, A. (2023). Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4. International Journal of Molecular Sciences, 24(20), Article 15134. DOI: 10.3390/ijms242015134.

Alsalloum, A. (2023). Immunoregulatory properties of erythroid nucleated cells induced from CD34+ progenitors from bone marrow. PLOS ONE, 18(6), Article e0287793. DOI: 10.1371/journal.pone.0287793. ISSN: 1932-6203.

Alsalloum, A. (2023). The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy? Cancers, 15(6), Article 1779. DOI: 10.3390/cancers15061779.

Alsalloum, A. (2022). Phenotypic and functional features of in vitro generated TCR-T cells specific for the tumor-associated antigen NY-ESO-1. Immunologiya, 43(5), 536-547. DOI: 10.33029/0206-4952-2022-43-5-536-547.

Alsalloum, A. (2022). Study of MAGE-A4 specific TCR-like CAR-T lymphocytes in vitro. Immunologiya, 43(4), 401-411. DOI: 10.33029/0206-4952-2022-43-4-401-411.

Omar Ahmed-Farid | Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Posted on by ScienceFather

Assoc Prof Dr. Omar Ahmed-Farid | Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

2004, EDA, Egypt

Dr. Omar Abdel-Hamed Ahmed-Farid is a highly qualified candidate for the Research for Best Researcher Award. With a robust academic and professional background, Dr. Farid has significantly impacted the field of physiology and analytical chemistry. His impressive citation metrics—1889 citations, an H-index of 24, and an I10-index of 61—highlight his influential research. As the Unit Administration Manager at the Egyptian Drug Authority, he excels in regulatory compliance, quality assurance, and team leadership. His previous roles include Technical Manager and Drug Quality Control Specialist, where he managed laboratory practices and ensured adherence to international standards. Dr. Farid’s contributions to policy development and staff training further demonstrate his dedication to advancing industry standards and professional excellence. His extensive research experience, combined with his leadership in regulatory and quality assurance roles, makes him a strong contender for this award.

Profile:

Education

Dr. Omar Abdel-Hamed Ahmed-Farid has a distinguished educational trajectory that underscores his expertise in physiology and analytical chemistry. He began his academic journey as an Assistant Researcher in Physiology in 2005, gradually advancing through roles as an Assistant Researcher, Researcher, and ultimately becoming an Associate Professor of Physiology in 2020. His progression reflects a deepening of knowledge and a growing commitment to the field. Dr. Farid’s education has been marked by hands-on experience and rigorous training in high-performance analytical techniques, such as High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC). This solid educational foundation has been instrumental in his success in research, quality assurance, and regulatory compliance within the pharmaceutical and medical diagnostics sectors. His academic background is a testament to his dedication to advancing scientific knowledge and improving industry standards

Professional Experience

Dr. Omar Abdel-Hamed Ahmed-Farid’s professional experience showcases a profound impact on the fields of physiology and analytical chemistry. As the Unit Administration Manager of Diagnostic Kits and Medical Supplies at the Egyptian Drug Authority (EDA), he oversees regulatory compliance, quality assurance, and documentation, ensuring adherence to national and international standards. His previous role as Technical Manager involved the implementation and maintenance of ISO-17025 and GLP standards, critical for maintaining laboratory accuracy and reliability. Dr. Farid’s extensive experience also includes managing laboratory equipment procurement and validation, as well as training staff on analytical techniques and quality protocols. His contributions to policy development and regulatory practices highlight his leadership and commitment to advancing industry standards. His career trajectory, from Drug Quality Control Specialist to Associate Professor, reflects a deep and evolving expertise, underpinned by a dedication to both scientific excellence and professional development.

Research Skill

Dr. Omar Abdel-Hamed Ahmed-Farid possesses a robust set of research skills, underscored by his extensive experience and academic background. His proficiency in analytical techniques such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Spectrophotometry highlights his capability to conduct precise and comprehensive biochemical analyses. Dr. Farid has demonstrated expertise in determining neurotransmitters, amino acids, and cellular metabolites, utilizing advanced methods like Atomic Absorption Spectroscopy and ELISA techniques. His research includes investigating enzymatic and non-enzymatic antioxidants, analyzing tissue samples using the Comet Assay, and studying animal blood pressure. His ability to apply complex analytical methods and maintain high standards in research protocols is further evidenced by his contributions to method validation and compliance with international standards. Dr. Farid’s analytical skills, combined with his commitment to quality and innovation, underscore his exceptional research capabilities.

Award and Recognition

Dr. Omar Abdel-Hamed Ahmed-Farid has demonstrated exceptional expertise and dedication in the field of physiology and analytical chemistry, earning widespread recognition for his impactful research and professional contributions. With 1889 citations, an H-index of 24, and a Researchgate score of 46.42, his scholarly work has significantly influenced the scientific community. As the Unit Administration Manager at the Egyptian Drug Authority, Dr. Farid has excelled in ensuring regulatory compliance, maintaining high-quality standards, and leading a team dedicated to advancing diagnostic practices. His commitment to policy development, training, and innovation underscores his role as a pivotal figure in the industry. Dr. Farid’s achievements reflect a remarkable blend of academic excellence and practical impact, making him a distinguished candidate for the Research for Best Researcher Award.

Conclusion

Dr. Omar Abdel-Hamed Ahmed-Farid’s comprehensive research contributions, extensive professional experience, and leadership in regulatory and quality assurance roles make him a highly suitable candidate for the Research for Best Researcher Award. His impact on the field through his research, coupled with his commitment to advancing regulatory practices and training, aligns well with the criteria for this prestigious award.

Publication Top Notes

  • Publication Title: Recombinant Interleukin − 2 Immunotherapy Ameliorates Inflammation and Promotes the Release of Monoamine Neurotransmitters in the Gut-Brain Axis of Schistosoma mansoni-Infected Mice
    • Authors: Mehran, H.S., Nady, S., Kassab, R.B., Ahmed-Farid, O.A., El-Hennamy, R.E.
    • Journal: Journal of Neuroimmune Pharmacology
    • Year: 2024
    • Volume: 19
    • Issue: 1
    • Pages: 37
    • Citations: 0
  • Publication Title: Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway
    • Authors: El-Marasy, S.A., AbouSamra, M.M., Moustafa, P.E., Galal, A.F., Farouk, H., Ahmed-Farid, O.A.
    • Journal: Scientific Reports
    • Year: 2024
    • Volume: 14
    • Issue: 1
    • Article Number: 13559
    • Citations: 0
  • Publication Title: The study of wound healing activity of Thespesia populnea L. bark, an approach for accelerating healing through nanoparticles and isolation of main active constituents
    • Authors: Abdel Halim, M.B., Eid, H.H., El Deeb, K.S., Ahmed-Farid, O.A., El Messiry, H.M.
    • Journal: BMC Complementary Medicine and Therapies
    • Year: 2024
    • Volume: 24
    • Issue: 1
    • Article Number: 85
    • Citations: 0
  • Publication Title: Eugenol alleviates acrylamide-induced rat testicular toxicity by modulating AMPK/p-AKT/mTOR signaling pathway and blood–testis barrier remodeling
    • Authors: Saleh, D.O., Baraka, S.M., Jaleel, G.A.A., Hassan, A., Ahmed-Farid, O.A.
    • Journal: Scientific Reports
    • Year: 2024
    • Volume: 14
    • Issue: 1
    • Article Number: 1910
    • Citations: 1
  • Publication Title: Gastro-Protective, Antioxidant, and Anti-Inflammatory Potential of Three Vegetable Oils Against Indomethacin-Induced Gastric Ulceration in Rats: in Vivo and in Vitro Study
    • Authors: Mohamed, M.M., Ahmed-Farid, O.A.
    • Journal: Egyptian Journal of Chemistry
    • Year: 2024
    • Volume: 67
    • Issue: 7
    • Pages: 341–359
    • Citations: 0
  • Publication Title: A combined administration of GABA agonist and L-histidine synergistically alleviates obesity-induced neuro-lipotoxicity and distorted metabolic transcriptome
    • Authors: Al-Malki, E.S., Ahmed-Farid, O.A., Moustafa, M.M.A., Linhardt, R.J., Warda, M.
    • Journal: Scientific African
    • Year: 2024
    • Volume: 24
    • Article Number: e02177
    • Citations: 0
  • Publication Title: Tolerability of Artemisia absinthium in anorexia: Targeting of neuronal appetite and satiety in zinc deficiency diet rat model
    • Authors: El-bakry, K.A.-E.K.M., Bahnasawy, M.H., Deef, L.E., Ahmed-Farid, O.A.-H., El-Naeli, S.S.B.
    • Journal: Scientific African
    • Year: 2024
    • Volume: 24
    • Article Number: e02162
    • Citations: 0
  • Publication Title: Zinc Oxide Nanoparticles Attenuated Neurochemical and Histopathological Alterations Associated with Aluminium Chloride Intoxication in Rats
    • Authors: Attia, F.M., Kassab, R.B., Ahmed-Farid, O.A., Abdel Moneim, A.E., El-Yamany, N.A.
    • Journal: Biological Trace Element Research
    • Year: 2024
    • Volume: (in press)
    • Citations: 0
  • Publication Title: Neurological study on the effect of CeNPs and/or La Cl3 on adult male albino rats
    • Authors: Abdel-Rahman, M., Elmasry, H.M., Ahmed-Farid, O.A., Hegazy, S.M., Rezk, M.M.
    • Journal: Journal of Trace Elements in Medicine and Biology
    • Year: 2024
    • Volume: 81
    • Article Number: 127323
    • Citations: 2
  • Publication Title: Nanoliposomal amino acids counteracting protein malnutrition induced hematopoietic and hepatic complications
    • Authors: Ahmed, R.F., Elbaset, M.A., Farouk, H., Ahmed-Farid, O.A.H., Nasr, M.
    • Journal: Journal of Drug Delivery Science and Technology
    • Year: 2023
    • Volume: 89
    • Article Number: 105051
    • Citations: 0

 

Rashna Mirza | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Ms. Rashna Mirza | Pharmaceutical Science | Best Researcher Award

PhD scholar of Quaid-i-Azam University, Pakistan.

Rashna Mirza is a distinguished researcher currently pursuing a PhD at Quaid-i-Azam University, Islamabad, focusing on advanced drug delivery systems, including brain-targeted transfersomes and optimized nano-transfersomes. A Gold Medalist in Pharm D from People’s University of Medical and Health Sciences for Women, she has demonstrated exceptional academic and research prowess. Her professional experience includes roles in quality assurance, pharmaceutical research, and laboratory supervision, showcasing her expertise in drug formulation and optimization. Rashna’s commitment to the field is reflected in her impactful publications and active participation in conferences. Her strengths lie in cutting-edge research, scientific communication, and organizational skills, though expanding her research impact and gaining leadership experience could further enhance her profile. Rashna’s background and achievements make her a strong candidate for the Research for Best Researcher Award.

Profile

Education

Rashna Mirza’s educational background reflects her strong commitment to the field of pharmaceutics. She is currently pursuing a PhD at Quaid-i-Azam University, Islamabad, with research focused on advanced drug delivery systems, including brain targeting of Cefepime-loaded transfersomes and optimization of nano-transfersomes for transdermal delivery. Prior to her PhD, Rashna completed her M.Phil at the same institution, where she continued to build on her expertise in pharmaceutics. She earned her Pharm D from People’s University of Medical and Health Sciences for Women, where she graduated as a Gold Medalist, underscoring her exceptional academic performance. Rashna’s foundational education includes an FSC Pre-Medical from Government Girls Degree College, Islamabad, and matriculation from Foundation Public School, Karachi. This robust educational background has equipped her with a deep understanding of pharmaceutical sciences and a solid foundation for her research career.

Professional Experience

Rashna Mirza has a diverse professional background that underscores her expertise in pharmaceutics and drug development. Currently pursuing her PhD at Quaid-i-Azam University, she is engaged in pioneering research on brain-targeted drug delivery systems and transdermal gels. Her experience includes working as a Lab Demonstrator at Quaid-i-Azam University, where she managed laboratory work, supervised experiments, and facilitated instructional activities. She also served as a Quality Assurance Inspector at Herbiotics, where she conducted inspections, quality audits, and process monitoring. Additionally, Rashna worked as a Retail Pharmacist at Punjab Pharmacy, handling inventory management, patient counseling, and medication therapy management. Her academic journey is marked by her gold medal achievement in Pharm D from People’s University of Medical and Health Sciences for Women. Her professional roles reflect her strong organizational, supervisory, and research skills, contributing significantly to her field.

Research Interest

Rashna Mirza’s research interests center on the development and optimization of novel drug delivery systems to enhance therapeutic outcomes. Her current PhD research focuses on innovative approaches such as brain-targeting of Cefepime-loaded transfersomes and the formulation of nano-transfersomes-based chitosan gels for transdermal delivery. This work aims to improve drug efficacy and patient compliance through advanced delivery mechanisms. Rashna is also interested in the formulation and optimization of thermosensitive in situ gels, exploring their potential for controlled and targeted drug release. Her research integrates both in vitro and in vivo studies to address challenges in pharmaceutical science, emphasizing the importance of precise drug delivery for effective treatment. Rashna’s work is characterized by a commitment to advancing pharmaceutics through rigorous experimentation and collaboration, contributing valuable insights to the field and aiming to bridge gaps in current drug delivery technologies.

Research Skills

Rashna Mirza exhibits a strong suite of research skills that underscore her capabilities in advancing the field of pharmaceutics. Her expertise in drug formulation and optimization is evident through her current PhD research, which involves innovative drug delivery systems such as brain-targeting transfersomes and nano-transfersomes. Rashna’s proficiency in statistical design and optimization further enhances her ability to develop and refine novel drug delivery methods. Her hands-on laboratory skills are complemented by her experience in quality assurance and process monitoring, ensuring meticulous evaluation and control of research processes. Additionally, Rashna’s solid background in scientific communication and report writing enables her to effectively present and disseminate research findings. Her involvement in interdisciplinary collaboration and active participation in conferences reflects her commitment to integrating diverse perspectives and advancing scientific knowledge. Overall, Rashna’s research skills demonstrate a well-rounded and impactful approach to pharmaceutics and drug development.

Award and Recognition

Rashna Mirza, a distinguished researcher and Gold Medalist in Pharm D, has garnered significant recognition for her contributions to the field of pharmaceutics. Her innovative research on drug delivery systems, including brain-targeting transfersomes and nano-transfersome optimization, has been widely acknowledged within the scientific community. Rashna’s work is prominently featured in impactful publications, reflecting her dedication to advancing drug formulation and optimization. Her role as a Lab Demonstrator and Quality Assurance Inspector highlights her exceptional skills in scientific communication, process improvement, and interdisciplinary collaboration. Additionally, Rashna’s participation in notable conferences and her involvement in quality audits further underscore her commitment to excellence in pharmaceutical research. These achievements collectively affirm her as a leading figure in her field, earning her well-deserved recognition and positioning her as a promising candidate for prestigious awards in pharmaceutics and drug development.

Conclusion

Rashna Mirza’s strong background in pharmaceutics, demonstrated research capabilities, and commitment to advancing drug delivery systems position her as a suitable candidate for the Research for Best Researcher Award. Her strengths in innovative research, academic excellence, and effective communication support her candidacy, while opportunities for broader impact and leadership development could further enhance her profile.

Publication Top Notes

  • Brain targeting of cefepime loaded transfersomes based thermosensitive in situ gel via intranasal delivery: In vitro and in vivo studies
    • Authors: R. Mirza, A.U. Khan, K.U. Shah, F. Alasmari, Z. Hafeez
    • Year: 2024
    • Citations: 1
  • Statistical design and optimization of nano-transfersomes based chitosan gel for transdermal delivery of cefepime
    • Authors: R. Mirza, K.U. Shah, A.U. Khan, Z. Hafeez, S.U. Haq
    • Year: 2024